Bicycle Therapeutics (NASDAQ:BCYC) posted its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.05, Fidelity Earnings reports. The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $1.00 million.
Shares of NASDAQ:BCYC opened at $8.45 on Friday. The firm’s fifty day moving average price is $9.98. Bicycle Therapeutics has a 12-month low of $6.24 and a 12-month high of $14.91.
Several research analysts have issued reports on BCYC shares. Canaccord Genuity set a $22.00 price target on Bicycle Therapeutics and gave the company a “buy” rating in a report on Monday, September 30th. Zacks Investment Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 7th. Finally, Goldman Sachs Group raised shares of Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $19.50.
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Read More: What is basic economics?
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.